Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

3.185 -0.155 (-4.64%)
Streaming Delayed Price Updated: 1:55 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenetic Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of... 
Via Benzinga
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Via ACCESSWIRE
US Judge Weighs Nationwide Ban On Abortion Pills
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
 
Via Benzinga
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
Via ACCESSWIRE
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's trading, 293 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Via ACCESSWIRE
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process. 
Via Benzinga
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
Via ACCESSWIRE
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
Via ACCESSWIRE
Stocks That Hit 52-Week Lows On Friday
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer
Via ACCESSWIRE
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology... 
From Xenetic Biosciences, Inc.
Via AccessWire
Topics Intellectual Property
JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences
- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET - 
From JTC Team, LLC
Via AccessWire
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET 
From Xenetic Biosciences, Inc.
Via AccessWire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.